According to a systematic review and meta-analysis, serum IGF1 levels in MASLD patients were significantly lower than those in the healthy control group, with this difference being particularly pronounced in non-alcoholic steatohepatitis (NASH) patients.43 The gene discussed is IGF1; the disease is metabolic dysfunction-associated steatohepatitis.